Search

everythinglearnresearchcommunity

for

Search:↓

The L412F variant of TLR3 is linked to skin infections, more viral infections, and autoimmune issues.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

Dual TCR Treg cells are common in mouse tissues and vary by location.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Anti-CD19 therapy may help treat SLE and NMOSD.

CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

NXC736 significantly reduced hair loss in mice with alopecia areata.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

LGD1069 effectively prevents breast tumors in mice without toxicity.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

Mononuclear cells may protect against certain chemotherapy-induced hair loss.

A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

Blocking LFA-1 prevents hair loss in mice.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

A new TP63 mutation was found in a baby with EEC syndrome, showing the need for TREC testing to check for immune issues.